[3PS-070]
Needle-Free Intranasal Nanovaccine with TLR7/8 Agonist for Immunotherapy of Metastatic Cancer
발표자김병덕 (성균관대학교)
연구책임자정지훈 (성균관대학교)
Abstract
Recent outbreaks and the global spread of infectious diseases have highlighted the need for mucosal vaccines, which can induce both antigen-specific humoral and cellular immune responses. Since systemic vaccines are generally ineffective at generating mucosal immunity, needle-free mucosal vaccines are important for disease prevention and mass immunization. However, low antigen stability at mucosal sites remains a challenge. In this study, we developed a cationic polymeric nanoparticle (DA3) platform that co-delivers the TLR7/8 agonist resiquimod (R848) and anionic ovalbumin (OVA) to enhance antigen stability and immune responses. The DA3/R848/OVA nanovaccine demonstrated superior dendritic cell activation, suppressed tumor growth in a B16-OVA melanoma model, induced immunological memory, and improved antitumor effects and survival following intranasal delivery, supporting its potential as a needle-free mucosal vaccine.